| __timestamp | Alkermes plc | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 51796000 |
| Thursday, January 1, 2015 | 4019000 | 72758000 |
| Friday, January 1, 2016 | 2301000 | 61008000 |
| Sunday, January 1, 2017 | 7232000 | 66962000 |
| Monday, January 1, 2018 | 68895000 | 84888000 |
| Tuesday, January 1, 2019 | 52816000 | 107068000 |
| Wednesday, January 1, 2020 | 1946000 | 122964000 |
| Friday, January 1, 2021 | 1020000 | 208808000 |
| Saturday, January 1, 2022 | 393842000 | 253297000 |
| Sunday, January 1, 2023 | 270806000 | 216566000 |
| Monday, January 1, 2024 | 245326000 |
Data in motion
In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Alkermes plc and BioCryst Pharmaceuticals, Inc. have demonstrated varying levels of investment in R&D, reflecting their strategic priorities.
From 2014 to 2023, BioCryst Pharmaceuticals consistently increased its R&D spending, peaking in 2022 with a 390% increase from 2014. This upward trend underscores BioCryst's aggressive pursuit of new drug development. In contrast, Alkermes plc showed a more volatile pattern, with a significant spike in 2022, marking a 4,970% increase from its 2014 spending. This suggests a strategic pivot towards innovation in recent years.
These trends highlight the dynamic nature of R&D investment strategies in the pharmaceutical sector, where companies must balance immediate financial performance with long-term innovation goals.
Comparing Innovation Spending: Novo Nordisk A/S and BioCryst Pharmaceuticals, Inc.
Research and Development Investment: AbbVie Inc. vs BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Sarepta Therapeutics, Inc. and Alkermes plc
Who Prioritizes Innovation? R&D Spending Compared for Alkermes plc and Veracyte, Inc.
R&D Insights: How Alkermes plc and ImmunityBio, Inc. Allocate Funds
R&D Spending Showdown: Alkermes plc vs Ligand Pharmaceuticals Incorporated
Alkermes plc vs Novavax, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Alkermes plc vs Evotec SE
Who Prioritizes Innovation? R&D Spending Compared for Alkermes plc and Taro Pharmaceutical Industries Ltd.
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Travere Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.